IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Webhead who wrote (1539)	4/15/1998 10:38:00 AM
From: Roudy	Read Replies (1) of 1762

I spoke with IDEC's Investor Relations and they said they will have earnings out on Monday. They thought the reaction in the stock price yesterday was due to misinterpretation of the monthly sales numbers. The US sales numbers were 13.2M (Jan), 11.1M (Feb) and 10.9M (Mar). This does not add up to the 37.7M in sales that Genetech reported. The misinterpretation comes from 13.4M sales in March that Genetech would indicate. However this number represents sales other than US and some inventory build up for anticipated European approval. It is believed that some thought the 13.4M of sales was all US and it is actually 10.9M. Jan sales numbers are believed to show the pent up demand on initial launch. Sales are going well and they are pursuing to open up more market. Product has been an easy sale so far. In May they will present two abstracts at the ASCO Conference. One will be on Rituxan and Interferon, and the other will be a podium presentation on Rituxan and CHOP. Don

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next